Moderna scraps lead mRNA chikungunya candidate after phase 1, slowing push beyond prophylactic vaccines

Moderna has suffered an early blow to its move beyond prophylactic vaccines, revealing it won’t take the lead candidate in one of its core modalities into phase 2. The mRNA player removed the drug candidate from its pipeline after wrapping up a phase 1 dose-escalation study.